AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29398432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase cone-beam computed tomography (DP-CBCT)
Number of subjects: 42
Study 27180994 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lignocaine
Number of subjects: 50
Study 27180994 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine with vasoconstrictor
Number of subjects: 50
Study 24532111 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-thermocouple probe
Number of subjects: 100
Study 24532111 — intervention group
Group type: COMPARATOR
Intervention: Deflectable temperature probe
Number of subjects: 100
Study 22394471 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 (4 mg)
Number of subjects: 40
Study 22394471 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 (12 mg)
Number of subjects: 40
Study 22394471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20079620 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting methamphetamine
Number of subjects: 0
Study 20079620 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting heroin
Number of subjects: 0
Study 20079620 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting drugs (general)
Number of subjects: 0
Study 17630221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette pack with graphic image warning label
Number of subjects: 89
Study 17630221 — intervention group
Group type: COMPARATOR
Intervention: Cigarette pack with text-only warning label
Number of subjects: 89
Study 16277632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg rapid-release nicotine gum (RRNG)
Number of subjects: 319
Study 16277632 — intervention group
Group type: COMPARATOR
Intervention: 2 mg nicotine polacrilex gum (NPG)
Number of subjects: 319
Study 12804864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection of DTPw vaccine
Number of subjects: 849
Study 12804864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection of DTPa vaccine
Number of subjects: 849
Study 12804864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection of HibTITER vaccine
Number of subjects: 849
Study 12804864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection
Number of subjects: 849
Study 12804864 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral thigh injection
Number of subjects: 849
Study 10605191 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combinations including two nucleoside analogues and a potent protease inhibitor
Number of subjects: 0
Study 10605191 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir in association with AZT plus 3TC
Number of subjects: 0
Study 10605191 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors and triple therapy
Number of subjects: 0
Study 8947337 — intervention group
Group type: EXPERIMENTAL
Intervention: Semidepot perennial grass-pollen extract for 4 years
Number of subjects: 17
Study 8947337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenges after 4 years' immunotherapy
Number of subjects: 17
Study 1836098 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 100
Study 1836098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6755307 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy + calcitonin
Number of subjects: 45
Study 6755307 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy + calcifediol
Number of subjects: 45
Study 6755307 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 45
Study 30791079 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 15
Study 30791079 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise (LEx)
Number of subjects: 15
Study 30791079 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 15
Study 29069568 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (n=57)
Number of subjects: 116
Study 29069568 — intervention group
Group type: COMPARATOR
Intervention: Medical-therapy group (n=59)
Number of subjects: 116
Study 27405353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 200
Study 27405353 — intervention group
Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 200
Study 24382677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereaved informal caregivers of palliative care patients
Number of subjects: 84
Study 24382677 — intervention group
Group type: COMPARATOR
Intervention: General population (n=977)
Number of subjects: 84
Study 21971755 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation treatment protocol (30 sessions starting four days post-operation)
Number of subjects: 29
Study 21971755 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise alone)
Number of subjects: 29
Study 18990715 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic remission
Number of subjects: 125
Study 18990715 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional remission
Number of subjects: 125
Study 18990715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both symptomatic and functional remission (recovery)
Number of subjects: 125
Study 17499892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 81
Study 15367192 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine Antiseptic)
Number of subjects: 108
Study 15367192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse (Peridex)
Number of subjects: 108
Study 15367192 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol negative control
Number of subjects: 108
Study 16604577 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor kit version 1.0
Number of subjects: 634
Study 16604577 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA tubes
Number of subjects: 634
Study 16604577 — intervention group
Group type: COMPARATOR
Intervention: Monitor kit version 1.5
Number of subjects: 634
Study 10853696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute submaximal exercise with NO inhalation (mask)
Number of subjects: 7
Study 10853696 — intervention group
Group type: COMPARATOR
Intervention: Acute submaximal exercise without NO inhalation (no mask)
Number of subjects: 7
Study 8644685 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (13.5 mmol/d) plus pantothenate (1.4 mmol/d)
Number of subjects: 0
Study 8644685 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (0.20 mmol/kg)
Number of subjects: 0
Study 8644685 — intervention group
Group type: COMPARATOR
Intervention: Pantothenate supplementation (0.02 mmol/kg)
Number of subjects: 0
Study 1325076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin CY 216 (Fraxiparine) in a fixed dose
Number of subjects: 149
Study 1325076 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in doses adjusted according to the activated partial thromboplastin time
Number of subjects: 149
Study 6465619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day, Trental 400 tds.)
Number of subjects: 97
Study 6465619 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day)
Number of subjects: 97
Study 31839158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day)
Number of subjects: 500
Study 31839158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 29329305 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF monotherapy (n = 111)
Number of subjects: 169
Study 29329305 — intervention group
Group type: COMPARATOR
Intervention: LAM+ADV combination therapy (n = 58)
Number of subjects: 169
Study 29329305 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF monotherapy (n = 111) with cirrhosis
Number of subjects: 169
Study 26823540 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent rotavirus vaccine (2 doses)
Number of subjects: 1393
Study 26823540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed vaccine schedules (3 doses)
Number of subjects: 1393
Study 26823540 — intervention group
Group type: COMPARATOR
Intervention: Single vaccine reference groups (2 doses)
Number of subjects: 1393
Study 25042313 — intervention group
Group type: EXPERIMENTAL
Intervention: New Formula
Number of subjects: 18
Study 25042313 — intervention group
Group type: COMPARATOR
Intervention: Old Formula
Number of subjects: 18
Study 22285609 — intervention group
Group type: EXPERIMENTAL
Intervention: multicomponent cognitive‐behavioral therapy (CBT)
Number of subjects: 93
Study 22285609 — intervention group
Group type: EXPERIMENTAL
Intervention: multicomponent cognitive‐behavioral therapy (CBT) with hypnosis
Number of subjects: 93
Study 22285609 — intervention group
Group type: COMPARATOR
Intervention: standard care (pharmacological treatment)
Number of subjects: 93
Study 19283745 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLT with concomitant ambulatory phlebectomies (EVLTAP)
Number of subjects: 50
Study 19283745 — intervention group
Group type: COMPARATOR
Intervention: EVLT alone
Number of subjects: 50
Study 17202433 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary modification + recombinant human growth hormone (GH) (0.1 mg/kg daily x 21 days, then 3 times/week)
Number of subjects: 24
Study 17202433 — intervention group
Group type: COMPARATOR
Intervention: Individualized dietary modification + placebo
Number of subjects: 24
Study 15771782 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 20536
Study 15771782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536
Study 12475853 — intervention group
Group type: EXPERIMENTAL
Intervention: Decelerating waveform
Number of subjects: 54
Study 12475853 — intervention group
Group type: COMPARATOR
Intervention: Constant square waveform
Number of subjects: 54
Study 12475853 — intervention group
Group type: COMPARATOR
Intervention: Sine waveform
Number of subjects: 54
Study 9791525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified education through a booklet about amblyopia and its treatment.
Number of subjects: 0
Study 9791525 — intervention group
Group type: COMPARATOR
Intervention: Ordinary information provided at two departments of paediatric ophthalmology.
Number of subjects: 0
Study 7702027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g fish-oil concentrate/d (approximately 3.4 g eicosapentaenoic and docosahexaenoic acids/d)
Number of subjects: 511
Study 7702027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 511
Study 7702027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g fish-oil concentrate/d
Number of subjects: 511
Study 31596518 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL‐18 concentrations measured at admission, discharge, 1 month, and 6 months
Number of subjects: 16636
Study 31596518 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL‐18 levels
Number of subjects: 16636
Study 31596518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression models
Number of subjects: 16636
Study 31596518 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for clinical risk factors and biomarkers (cTnT‐hs, NT‐proBNP, cystatin C, CRP‐hs, and GDF‐15)
Number of subjects: 16636
Study 31596518 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐18 concentrations
Number of subjects: 16636
Study 31596518 — intervention group
Group type: EXPERIMENTAL
Intervention: No associations with sMI
Number of subjects: 16636
Study 27530310 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg/day for two consecutive days
Number of subjects: 24
Study 27530310 — intervention group
Group type: COMPARATOR
Intervention: PLEX 1-L plasma exchange five times with 5% albumin replacement fluid, every other day, 10-30 days before the procedure
Number of subjects: 24
Study 25447038 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min in-situ IHCA training sessions every two months (2M)
Number of subjects: 0
Study 25447038 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min in-situ IHCA training sessions every three months (3M)
Number of subjects: 0
Study 25447038 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min in-situ IHCA training sessions every six months (6M)
Number of subjects: 0
Study 25447038 — intervention group
Group type: COMPARATOR
Intervention: Standard AHA training (C)
Number of subjects: 0
Study 23576043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic red wine (RW) consumption
Number of subjects: 10
Study 23576043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute red wine (RW) intake with fat overload
Number of subjects: 10
Study 21216855 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT
Number of subjects: 255
Study 19514093 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS
Number of subjects: 65
Study 16205904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose treatment
Number of subjects: 338
Study 16205904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose treatment
Number of subjects: 338
Study 16205904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 15456623 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy administered in the initiation phase according to a cluster schedule of eight doses injected on four visits.
Number of subjects: 191
Study 15456623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy).
Number of subjects: 191
Study 11287014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 62
Study 11287014 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 62
Study 9237962 — intervention group
Group type: COMPARATOR
Intervention: Olestra 0 g/d
Number of subjects: 102
Study 9237962 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 8 g/d
Number of subjects: 102
Study 9237962 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 20 g/d
Number of subjects: 102
Study 9237962 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 32 g/d
Number of subjects: 102
Study 9237962 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 2.1 mg d‐alpha‐tocopheryl acetate and 0.06 microg ergocalciferol per gram of olestra
Number of subjects: 102
Study 9237962 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (all doses)
Number of subjects: 102
Study 8233263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear, hand, and foot reflexology treatment
Number of subjects: 35
Study 8233263 — intervention group
Group type: COMPARATOR
Intervention: Placebo reflexology
Number of subjects: 35
Study 3317354 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 2 months
Number of subjects: 80
Study 3317354 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 6 months
Number of subjects: 80
Study 31378406 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral antegrade cerebral perfusion
Number of subjects: 184
Study 31378406 — intervention group
Group type: COMPARATOR
Intervention: Unilateral antegrade cerebral perfusion
Number of subjects: 184
Study 29907128 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Programme 10-14 (SFP 10-14 or 'Familias Fuertes') alongside services-as-usual
Number of subjects: 840
Study 29907128 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual
Number of subjects: 840
Study 27225988 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 931
Study 27225988 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy only (no stenting)
Number of subjects: 931
Study 27225988 — intervention group
Group type: COMPARATOR
Intervention: Overall CKD outcomes
Number of subjects: 931
Study 27225988 — intervention group
Group type: COMPARATOR
Intervention: Overall cardiovascular disease outcomes
Number of subjects: 931
Study 23996068 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB reconstruction with synthetic degradable augmentation device
Number of subjects: 201
Study 23996068 — intervention group
Group type: COMPARATOR
Intervention: BPTB reconstruction without augmentation
Number of subjects: 201
Study 23996068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without augmentation)
Number of subjects: 201
Study 23451449 — intervention group
Group type: EXPERIMENTAL
Intervention: Plygersic gel (4% ginger and plai extract)
Number of subjects: 100
Study 23451449 — intervention group
Group type: COMPARATOR
Intervention: 1% Diclofenac gel
Number of subjects: 100
Study 19902277 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma disc decompression (PDD)
Number of subjects: 115
Study 19902277 — intervention group
Group type: COMPARATOR
Intervention: Conservative care (CC)
Number of subjects: 115
Study 18318721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) - 560-nm filter, 30 J/cm², 2.4/4.0-ms pulse with 10-ms delay, three treatments spaced 1 month apart
Number of subjects: 10
Study 18318721 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser - 3.8 J/cm², 30% pattern overlap, 0% interpulse overlap, 15 microm per pass, three treatments spaced 1 month apart
Number of subjects: 10
Study 15833457 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal cemented resurfacing hip replacement
Number of subjects: 0
Study 15833457 — intervention group
Group type: COMPARATOR
Intervention: Cemented total hip replacement
Number of subjects: 0
Study 12744873 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 395
Study 12744873 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented children (Control)
Number of subjects: 395
Study 10482323 — intervention group
Group type: EXPERIMENTAL
Intervention: Three hourly nebulized salbutamol
Number of subjects: 63
Study 10482323 — intervention group
Group type: COMPARATOR
Intervention: Four hourly nebulized salbutamol
Number of subjects: 63
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-beam with a custom block (HB+CB)
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-beam using asymmetric collimator jaw (HB/AJ)
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-beam using asymmetric collimator jaw with custom block (H/AJ+CB)
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocentric technique with nondivergent posterior borders (JCRT technique)
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric jaw with no medial wedge
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial wedge (used in all techniques)
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric half-beam technique
Number of subjects: 0
Study 8621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerrobend half-beam blocking
Number of subjects: 0
Study 1751998 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg.kg‐1
Number of subjects: 60
Study 1751998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7141758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortimicin A 2.5 mg/kg
Number of subjects: 17
Study 7141758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortimicin A 5.0 mg/kg
Number of subjects: 17
Study 7141758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortimicin A 7.5 mg/kg
Number of subjects: 17
Study 7141758 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean beta-phase half-life
Number of subjects: 17
Study 30777113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellie Coping Kit for Children with Injury intervention
Number of subjects: 80
Study 30777113 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 80
Study 30030322 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM plus Check Your Drinking (CYD)
Number of subjects: 986
Study 30030322 — intervention group
Group type: COMPARATOR
Intervention: MoodGYM
Number of subjects: 986
Study 26978668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-quit reduction in anxiety sensitivity
Number of subjects: 195
Study 26978668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity class membership
Number of subjects: 195
Study 25256892 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia treatment at 38.7-39°C for 60 minutes
Number of subjects: 16
Study 25256892 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia treatment
Number of subjects: 16
Study 21362636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HYP)
Number of subjects: 36
Study 21362636 — intervention group
Group type: COMPARATOR
Intervention: Active attention control (CON)
Number of subjects: 36
Study 20093825 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal progenitor/stem cell therapy
Number of subjects: 0
Study 20093825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytopheretic membranes
Number of subjects: 0
Study 20093825 — intervention group
Group type: COMPARATOR
Intervention: Smart immunomodulatory membrane
Number of subjects: 0
Study 18059593 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1 g.kg(‐1).d(‐1))
Number of subjects: 15
Study 18059593 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (70 mg.kg(‐1).d(‐1))
Number of subjects: 15
Study 18059593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carbohydrate and glutamine supplementation
Number of subjects: 15
Study 18059593 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 15
Study 16026373 — intervention group
Group type: EXPERIMENTAL
Intervention: Close glycaemic control intervention
Number of subjects: 1
Study 16026373 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 11843508 — intervention group
Group type: EXPERIMENTAL
Intervention: Homograft (group H)
Number of subjects: 15
Study 11843508 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle xenograft (group F)
Number of subjects: 15